<DOC>
	<DOC>NCT00617877</DOC>
	<brief_summary>The purpose of this study is to evaluate the antihypertensive response of treatment with losartan with reference to genetic polymorphisms.</brief_summary>
	<brief_title>Antihypertensive Response to Losartan and Genetic Polymorphisms</brief_title>
	<detailed_description />
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Both gender less than 60 years old, with mildmoderate hypertension (SBP greater than and DBP equal or greater than 90 mmhg, BP &lt; 180/110) Never treated for hypertension or who have taken antihypertensive agents sporadically (not more than 15 days total therapy) but not in the 30 days prior to the first visit Patient in therapeutic wash out for 6 months Patient is asymptomatic, absence of significant concomitant diseases, except for nonfamilial hypercholesterolemia, absence of systemic diseases Women with menopause not treated with hormone replacement therapy or women of reproductive age who do not make use of estroprogestagen agents but who use another safe contraceptive method BMI &lt; 30 for men and &lt; 28 for women Secondary or malignant hypertension, Na &lt;130 mmol/l, K &gt;5,5 mmol/l, or &lt; 3,0 mmol/l Cardiac disease such as ischemic, HF, arrhythmia, cardiac surgery Pregnant, breast feeding History of nephropathy, metabolic disease, liver disease Alcohol or drug abuse History of angioedema Has a known hypersensibility to study drug(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>